Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for NUPR1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | NUPR1 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Theoretical MW optimized for biophysical assays. |
View NUPR1 Products |
| Gene Delivery | NUPR1 Promise-ORF / Lentivirus Full-length ORF for stable cell lines and nuclear translocation assays. |
View NUPR1 Products |
| Benchmark Ab | Anti-NUPR1 Recombinant Antibody Recombinant positive control for Western Blot and Immunofluorescence. |
View NUPR1 Products |
| Validator | NUPR1 siRNA Set For knockdown verification in stress-response assays. |
View NUPR1 Products |
| Related Target A | MSN (Moesin) Direct binding partner of NUPR1; critical for NUPR1-dependent nuclear translocation and cell migration. |
View MSN Products |
| Related Target B | KRAS NUPR1 is a critical downstream mediator of KRAS-induced oncogenesis in pancreatic cancer. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intrinsically Disordered Protein (IDP) Aggregation | High Purity (>95%) and optimized buffer formulations to prevent non-specific aggregation in screening. |
| Protein-Protein Interaction (PPI) Screening | Sequence-verified functional domains and binding partners (e.g., MSN) expressed with native-like folding. |
| Lack of Controls | Clinical Benchmark Antibodies and validated control plasmids included. |
| False Positives | Validated siRNA sets included for target specificity and knockdown verification. |
Live NUPR1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for NUPR1 therapeutics is intensifying, with major players shifting focus from traditional mAbs to small-molecule inhibitors of protein-protein interactions (PPIs) and genetic modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting the disruption of NUPR1 interaction networks in chemotherapy-resistant solid tumors, particularly pancreatic ductal adenocarcinoma (PDAC).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (PPI Inhibitors) | Academic Consortia, Biotech Startups | Pancreatic Cancer, Glioblastoma | Biophysical Binding Assays (Need high-purity, monomeric NUPR1 protein) |
| RNA Therapeutics (siRNA/shRNA) | Preclinical Stage Biopharma | Metastatic Solid Tumors | In Vitro Knockdown Validation (Need sequence-validated siRNA and RT-qPCR controls) |
| Combination Therapies (with KRAS/MEK inhibitors) | Translational Medicine Labs | KRAS-mutant Cancers | Synergy Screening (Need co-expression lentiviruses for NUPR1 and mutant KRAS) |